Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Role of radiation therapy for local control of disease Nuran S Bese, MD Professor of Radiation Oncology Istanbul-Turkey Role of radiation therapy for local control of disease • Requirements for Safe and Effective Radiation Therapy • Early Stage Breast Cancer (Stage I and II) Whole-Breast Radiation Therapy (WBRT) Post-mastectomy Radiation Therapy (PMRT) • Locally Advanced Breast Cancer (LABC) Requirements for Safe and Effective Radiation Therapy for Breast Cancer Bese et al, Breast J. 2006 Jan-Feb;12 Suppl 1:S96-102 WHO Recommendations • 1 Radiation Oncologist /250 new cancer patients • 1 Megavoltage equipment / 300 new patients • 5 Megavoltage equipment / 1 million population • Actual supply of megavoltage equipment is only 18% of the estimated need. Barton et al. Lancet Oncol. 2006;7:584-595. Cobalt-60 Linear accelerator Advantages Disadvantages Advantages Disadvantages -Cheaper -More simple mechanical, electrical components and operations -Easy to maintain -Relative constancy of beam out-put, predictability of decay -QA program is simple -Poor field flatness -Lower % depth dose -Greater penumbra -Lower dose rate -Less favorable beam out-put -Need of changing source every 5 years -Inability to deliver complex treatments -Ability of delivering complex treatments -Better dose distribution especially after BCS -Decreased skin dose especially after BCS -Decreased dose to the contralateral breast -Preventive maintenance is essential, expensive and requires a maintenance technician - More detailed QA program is needed Other Requirements • Maintenance of the equipments • Education of the staff and patients • Logistic issues, geographic accessibility, support systems • Social security for health • Requirements for Safe and Effective Radiation Therapy • Early Stage Breast Cancer (Stage I and II) Whole-Breast Radiation Therapy (WBRT) Post-mastectomy Radiation Therapy (PMRT) • Locally Advanced Breast Cancer (LABC) Early Stage Breast Cancer (Stage I and II) Whole-Breast Radiation Therapy (WBRT) Conservation Surgery + RT Mastectomy Trial No. of Pts.* Tumor Size (cm) Tumor Control (%) DiseaseFree survival (%) Tumor Control (%) DiseaseFree Survival (%) Guy’s 182/188 <4 T1, 80 T2, 30 80 T1, 90 T2, 80 80 60 Milan 351/349 2 92 60 (20 y) 98 60 (20 y) NSABP 515/494 4 85 37 (20 y) 93 37 (20 y) NCI 121/116 5 88 63 (18 y) 90 67 (18 y) EORTC, 2000 466/436 5 80 60.5 88 66 (18 y) DBCG 430/429 5 97 70 96 66 G. Roussy 88/91 2 87 55 82 45 (15 y) *Number receiving conservation therapy plus RT/No. receiving mastectomy. BCS+RT / BCS Prospective Randomized Trials Study Local Overall Survival Recurrences(%) (%) BCS BCS+RT BCS BCS+RT Followup (year) NSABP 39 14 46 46 20 Milan III 23 6 77 82 10 Scotch 24 6 85 88 5 Sweden 24 8.5 78 78 10 Ontario 40 18 72 74 10 England 35 13 - - 5 Early Breast Trialists Coll Group Lancet 366:2087, 2005 BCS: Impact of Radiation Therapy on Long-term Survival Early Breast Cancer Trialists’ Collaborative Group: Lancet 355:1757, 2000 BCS: Impact of Radiation Therapy on Long-term Survival Early Breast Cancer Trialists’ Collaborative Group: Lancet 355:1757, 2000 Tangential breast field CONCLUSION: WBRT • Women deserves RT after BCS • Tamoxifen seems appropriate in older patients ( aged≥ 70) with ER+ cancers, particularly if serious co morbidities are present WBI± RLI: 46-50Gy over 5-6 weeks with 1.8-2Gy fractions EORTC BOOST TRIAL: 10 year-LC Bartelink et al, JCO 2007;25;3259 EORTC BOOST TRIAL • Central pathological review of 1616 patients • Boost reduced LR (HR=0.47) • Boost reduced LC for patients < 50years (HR=0.51) and for patients with G3 tumors (HR=0.42) • Boost is effective for younger or high grade tumors • No boost seems reasonable for older patients with grade 1,2 tumors Jones et al. JCO 2009;27:4939 Hypofractionated Schedules 140-month results of Canadian Accelerated WBRT Whelan T; J N Cancer Inst. 2002;94:1143 SABCS 2007 Abstract Alternative for women over 60 with G1,2 tumors. Resource sparing strategy Maximum attention for cardio toxicity ! APBI • Uncertainty about long term results; large fractionsvolumes • Learning curve is inevitable • Still investigational • Requirements for Safe and Effective Radiation Therapy • Early Stage Breast Cancer (Stage I and II) Whole-Breast Radiation Therapy (WBRT) Post-mastectomy Radiation Therapy (PMRT) • Locally Advanced Breast Cancer (LABC) PMRT: Randomized Trials DBCS 82-B/82-C • Number of dissected lymph nodes • CMF • Duration of Tamoxifen Overgaard M et al Radiother & Oncol 82: 247, 2007 PMRT: Randomized Trials British Columbia Locoregional recurrence free survival (all) overall survival (all) Ragaz et al.J Natl Cancer Inst 97,116-26, 2005 g Sir Richard Peto, San Antonio, dec 2006 EBCTCG PMRT for N0 • Should post mastectomy radiation therapy be systematic for pT2-pT3N0 breast cancer? • T2+ • Grade 2-3 • HR• LVI • Premenopausal • Close surgical margin <2mm • No systemic treatment PMRT: RT FIELDS • Patients with ≥ 4 lymph nodes: chest-wall +scf • Patients with<4 lymph nodes: chest-wall ± scf • Routine axillary irradiation (low axillary recurrence and the risk of arm oedema) inadequate axillary dissection patients with more than 10 involved lymph nodes Chang etal. IJROBP 2007 ;67:1043-51 Internal Mammary Chain RT • IMC RT is recommended for patients with clinically or pathologically positive internal mammary lymph nodes with the use of 3-D treatment planning. • IMC RT is considered if the primary tumor is located at the inner quadrant with other adverse risk factors • • Requirements for Safe and Effective Radiation Therapy • Early Stage Breast Cancer (Stage I and II) Whole-Breast Radiation Therapy (WBRT) Post-mastectomy Radiation Therapy (PMRT) • Locally Advanced Breast Cancer (LABC) Locally Advanced Breast Cancer • In low resource countries, 30-60% of patients present with LABC • Initial treatment is systemic therapy • No survival advantage of neoadjuvant CT • Inoperable tumors can become operable • Endocrine therapy is an alternative for HR+ • After response to CT: Mastectomy • Selected patients with non-inflammatory disease: BCS • Post-op RT is an essential component for LC • Inoperable tumors after cross resistant CT, pre-op RT 45-50Gy • CT→cross-resistant CT→in-op→RT45Gy→definitive RT LABC Local-regional recurrence for patients treated with RT ( 542 patients) and without RT (134 patients,) Huang, E. H. et al. J Clin Oncol; 22:4691-4699 2004 LABC: NEOADJUVANT CT LRR initial clinical stage III or IV tumors, subsequently achieved a path complete response Huang, E. H. et al. J Clin Oncol; 22:4691-4699 2004 • RT is the essential component of local treatment of Early and LABC • RT is an efficient tool for the palliation of metastatic disease